Idenix Pharmaceuticals Inc. (IDIX) Wednesday reported a wider loss for the second quarter, due mainly to higher costs and expenses.
The Cambridge, Massachusetts-based company's second-quarter net loss was $25.40 million or $0.23 per share, compared to $13.91 million or $0.15 per share last year. On average, 10 analysts polled by Thomson Reuters expected loss of $0.21 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenues for the quarter grew to $1.44 million from $1.04 million in the prior-year quarter. Ten analysts had a consensus revenue estimate of $1.42 million for the quarter.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.